Glucobay (Acarbose)

Glucobay is indicated for the oral treatment of type 2 diabetes mellitus, particularly when post‑prandial hyperglycemia is a concern.

• As monotherapy or adjunct therapy to diet and exercise for adults with type 2 diabetes.
• To reduce post‑meal blood glucose excursions after meals containing carbohydrates.
• In combination with other oral antidiabetic agents such as metformin or sulfonylureas.
• For patients who require additional glycemic control despite existing therapy.
• As part of a comprehensive diabetes management plan under medical supervision.

The safety profile of Glucobay includes a range of gastrointestinal and metabolic effects that vary in frequency.

Common

• Flatulence and abdominal distension due to increased intestinal gas production.
• Diarrhea or loose stools, typically occurring after meals rich in carbohydrates.
• Abdominal discomfort or cramping that may be transient.
• Mild nausea without vomiting.

Serious

• Severe hypoglycemia, particularly when Glucobay is used with insulin or insulin‑secretagogue agents.
• Hepatic dysfunction, manifested by significant elevations in liver transaminases.
• Allergic reactions, including rash, pruritus, or angioedema requiring medical attention.
• Rare reports of intestinal obstruction or paralytic ileus.

When prescribing Glucobay, clinicians consider several precautionary measures to ensure safe use and to minimize adverse outcomes.

• Assess renal and hepatic function before initiating therapy and monitor periodically.
• Use caution in patients with inflammatory bowel disease or a history of intestinal surgery.
• Adjust dose or discontinue if severe gastrointestinal symptoms develop.
• Evaluate risk of hypoglycemia when combined with insulin or sulfonylureas.
• Counsel patients on the importance of consistent carbohydrate intake to avoid unpredictable glucose levels.
• Avoid use during pregnancy and lactation unless clearly indicated by a healthcare professional.

Glucobay may interact with other medications, affecting glucose control or increasing the risk of side effects.

Avoid

• Concurrent use with high‑dose insulin or insulin secretagogues without dose adjustment, due to heightened hypoglycemia risk.
• Co‑administration with other alpha‑glucosidase inhibitors, which can amplify gastrointestinal adverse effects.

Use with caution

• Combination with metformin, as both may cause gastrointestinal discomfort.
• Use alongside drugs that affect hepatic metabolism, such as certain antifungals or antiretrovirals, requiring liver function monitoring.
• Concurrent administration of oral anticoagulants, as altered absorption may influence INR values.
• Use with beta‑blockers, which may mask symptoms of hypoglycemia.